PMID: 11905506Mar 22, 2002Paper

Thalidomide in myelodysplastic syndromes

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
F Zorat, G Pozzato

Abstract

The myelodysplastic syndromes are a heterogeneous group of clonal diseases of haemopoiesis, which are a challenge for both biologists and clinicians. In this paper the current classification and the recent advances in the understanding the disease mechanisms are reviewed. The recent therapeutic advances are also indicated, such as intensive and low-dose chemotherapy, new drugs, erythropoietin and colony-stimulating factors. However, the work has been focused on thalidomide, its therapeutic potential, its modes of actions, side effects, indications and future applications.

References

Jul 1, 1992·British Journal of Haematology·D J CulliganR A Padua
Apr 16, 1992·The New England Journal of Medicine·G B VogelsangJ R Wingard
Mar 1, 1991·The Journal of Experimental Medicine·E P SampaioG Kaplan
Jan 1, 1988·British Journal of Haematology·A TichelliB Speck
Oct 1, 1984·Arthritis and Rheumatism·O Gutiérrez-Rodríguez
Jun 1, 1982·British Journal of Haematology·J M BennettC Sultan
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoJ Folkman
Aug 1, 1993·The Journal of Infectious Diseases·E P SampaioE N Sarno
Jun 1, 1993·The Journal of Experimental Medicine·A L MoreiraG Kaplan
Dec 1, 1995·Leukemia Research·Y YoshidaH Kawabata
Dec 1, 1996·Clinical Immunology and Immunopathology·J D KlausnerG Kaplan
Feb 1, 1997·Leukemia & Lymphoma·H Enright, W Miller
May 17, 1997·Lancet·W AtoyebiJ S Wainscoat
Dec 24, 1997·British Journal of Haematology·J J MolldremA J Barrett
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Feb 17, 2000·Seminars in Hematology·N Frickhofen, S J Rosenfeld

❮ Previous
Next ❯

Citations

Apr 3, 2010·Hematology/oncology Clinics of North America·Elaine M Sloand, A J Barrett
Feb 4, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Amanda C Peltier, James W Russell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.